David Peng, MD, MPH

Chief Clinical Officer, Office of the SVP for Health Affairs

Professor of Clinical Dermatology

Image of David Peng, MD, MPH
Is this your profile? Click to edit

Overview

David Peng, M.D., M.P.H., came to the Keck School after three years at Stanford University School of Medicine, where he served as associate professor and director of the Department of Dermatology’s Residency Training Program, one of the nation’s most prestigious residency training programs in dermatology. He also served as chief of the Stanford Dermatology Clinics, director of the Medical Dermatology Program and director of the Allergic Contact Dermatitis Program in the Department of Dermatology. He originally joined the Keck School’s faculty in 2004 and was appointed visiting assistant professor of clinical medicine, associate residency program director in the division of dermatology, and director of the Contact Dermatitis Clinic. He was appointed director of the residency training program in 2008 and served as acting chair of the Department of Dermatology between November 2008 and July 2009. Peng received his bachelor’s degree from the University of California, Berkeley, and medical degree from the University of California, San Diego (UCSD). He completed his internship at UCLA, where he also earned a master of public health degree before returning to UCSD for his residency in dermatology.

Awards

  • UCLA-San Fernando Valley Internal Medicine Training Program: Alpha Omega Alpha Intern of the Year, 2001
  • Wright Foundation Grant Recipient, 2005
  • USC Keck School of Medicine: Outstanding Teaching Award, Division of Dermatology,, 2005
  • USC Keck School of Medicine: Outstanding Teaching Award Presented by the 2nd year students, 2005
  • Salerni Medical Educator’s Collegium: Elected Member, 2006
  • USC Keck School of Medicine: Outstanding Teaching Award Presented by the 4th year students, 2006
  • University of Southern California: Mellon Mentorship Award, 2008
  • USC Keck School of Medicine: Outstanding Teaching Award, Presented by the 1st year students, 2009
  • USC Keck School of Medicine: Master Teacher, 2009
  • Department of Dermatology, Stanford University: Teacher of the Year, 2011
  • Stanford University, Department of Internal Medicine: Teacher of the Year, Chief Resident’s Award, 2011

Publications

  • Development of Poliosis in Patients Treated With Immunotherapy for Metastatic Cutaneous and Non-Cutaneous Melanoma. Pigment Cell Melanoma Res. 2026 May; 39(3):e70089.. View in PubMed
  • Double bridge to heart transplantation: Outcomes of early versus delayed extracorporeal membrane oxygenation crossover in pediatric population. JTCVS Open. 2026 Apr; 30:101608.. View in PubMed
  • Predictors of Response to Cardiac Resynchronization Therapy in Pediatric Patients and Patients With Congenital Heart Disease. Circ Arrhythm Electrophysiol. 2025 Dec; 18(12):e013600.. View in PubMed
  • Everolimus and Low-Dose Tacrolimus After Heart Transplant in Children: A Randomized Clinical Trial. JAMA. 2025 Oct 21; 334(15):1339-1348.. View in PubMed
  • Critical care management of right ventricular failure in pediatric left ventricular assist devices: An advanced cardiac therapies improving outcomes network (ACTION) endorsed statement. JHLT Open. 2025 Nov; 10:100361.. View in PubMed
  • The ACTION VAD registry: A collective five-year experience. J Heart Lung Transplant. 2025 04; 44(4):530-540.. View in PubMed
  • Impact of MEK Inhibition on Childhood RASopathy-Associated Hypertrophic Cardiomyopathy. JACC Basic Transl Sci. 2025 Feb; 10(2):152-166.. View in PubMed
  • ACTION-ARC Pediatric and Adult Congenital Heart Disease Ventricular Assist Device Adverse Event Definitions-2023. ASAIO J. 2024 11 01; 70(11):911-919.. View in PubMed
  • Development and Validation of a Novel Pediatric Mechanical Circulatory Support Risk Stratification Tool: The Advanced Cardiac Therapies Improving Outcomes Network (ACTION) Ventricular Assist Device Score. ASAIO J. 2025 03 01; 71(3):270-275.. View in PubMed
  • Intravenous gentamicin therapy induces functional type VII collagen in patients with recessive dystrophic epidermolysis bullosa: an open-label clinical trial. Br J Dermatol. 2024 07 16; 191(2):267-274.. View in PubMed